| Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. | |
| | |
MedLine Citation:
|
PMID: 18649969 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: This study assessed first-line chemotherapy treatment patterns over time and identified predictors of chemotherapy use and treatment selection among elderly patients with newly diagnosed Stage IIIB/IV non-small cell lung cancer (NSCLC) in the United States. METHODS: Patients aged 65 years and older newly diagnosed with Stage IIIB/IV NSCLC between 1997 and 2002 were identified and followed through 2003 using the Surveillance, Epidemiology and End Results (SEER)-Medicare database to evaluate temporal trends in chemotherapy treatment. Multivariate logistic regression models were estimated to identify predictors of chemotherapy treatment and factors associated with use of cisplatin/carboplatin (platinum) and either a taxane or gemcitabine versus other treatments. RESULTS: Chemotherapy use increased from approximately 28% of Stage IIIB/IV NSCLC patients diagnosed in 1997 to 36% of patients diagnosed in 2002. Doublet therapy was most commonly used as first-line therapy, received by 74% of chemotherapy-treated patients across all study years. Use of doublet therapy with platinum and either a taxane or gemcitabine also increased over time (with the largest increase for gemcitabine combinations from 0.3% in 1997 to 11.8% in 2002). Males were more likely than females to be treated with chemotherapy (odds ratios [95% CI]: 1.14 [1.06-1.22]), as were patients in the Northeast and South relative to patients in the West (1.24 [1.13-1.36] and 1.33 [1.20-1.47], respectively). CONCLUSION: Use of first-line chemotherapy treatment among elderly Stage IIIB/IV NSCLC patients is low, but appears to be increasing, with potential regional and gender differences in treatment. These findings are likely to be of interest to clinicians and policymakers. |
| | |
Authors:
|
Kathleen Lang; Martin D Marciniak; Doug Faries; Michael Stokes; Don Buesching; Craig Earle; Joseph Treat; Nathalie Morissette; David Thompson |
Related Documents
:
|
11932909 - Trimodality treatment in stage iii nonsmall cell lung carcinoma: prrognostic impact of ... 12399129 - Blood vessel invasion in resected non small cell lung carcinomas is predictive of metas... 8765179 - Impact of tumor extent and location on treatment outcome in patients with stage iii non... 16293409 - Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice? 18226679 - Impact of staging transesophageal eus on treatment and survival in patients with non-sm... 10676559 - Combined modality therapy of non-small cell lung cancers. 7819079 - Ultrasound examination of pathological cervical lymph nodes in patients with non-hodgki... 6952959 - Normal sister chromatid exchange frequency in long-term survivors with acute leukemia. 9374239 - Extended anterior craniofacial resection for intracranial extension of malignant tumors. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2008-07-22 |
Journal Detail:
|
Title: Lung cancer (Amsterdam, Netherlands) Volume: 63 ISSN: 0169-5002 ISO Abbreviation: Lung Cancer Publication Date: 2009 Feb |
Date Detail:
|
Created Date: 2009-01-06 Completed Date: 2009-03-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8800805 Medline TA: Lung Cancer Country: Ireland |
Other Details:
|
Languages: eng Pagination: 264-70 Citation Subset: IM |
Affiliation:
|
i3 Innovus, Medford, MA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Carcinoma, Non-Small-Cell Lung / drug therapy* Female Humans Lung Neoplasms / drug therapy* Male Retrospective Studies SEER Program |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Considering something 'ELSE': ethical, legal and socio-economic factors in medical imaging and medic...
Next Document: In situ iron activated persulfate oxidative fluid sparging treatment of TCE contamination--a proof o...